Navigation Links
Repligen Reports First Quarter Fiscal Year 2010 Financial Results
Date:8/6/2009

on will receive either RG2417 or a placebo twice a day for eight weeks. The study is designed to assess the safety and efficacy of RG2417 on the symptoms of depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) and the Clinical Global Impression of Change in Bipolar Disorder scale (CGI-BP-C). In March, Repligen exclusively licensed worldwide rights to a patent application from McLean Hospital for the use of uridine in the treatment of patients with bipolar disorder. If issued, the patent would remain in force until at least 2025. More than five million adults worldwide have bipolar disorder.

HDAC Inhibitors for Friedreich's Ataxia

We are currently developing inhibitors of histone deacetylase enzymes (HDACs) for the treatment of inherited neurodegenerative diseases such as Friedreich's ataxia. Preclinical studies have shown that specific HDAC inhibitors increase production of the protein frataxin which may have the potential to arrest disease progression in patients with Friedreich's ataxia. We have identified several potential clinical candidates and are further characterizing these leads in preclinical models for their pharmacologic, toxicologic and pharmacodynamic profiles.

Quarterly Conference Call

Repligen will host a conference call and webcast on Thursday, August 6th at 10:00 a.m. EDT, to review financial results. This call can be accessed via Repligen's website at www.repligen.com or by calling (800) 638-4930 for domestic calls and (617) 614-3944 for international calls. Participants must provide the following passcode: 65889469.

About Repligen Corporation

Repligen Corporation is a biopharmaceutical company focused on the development of novel therapeutics for neurological disorders. In addition, we are the world's leading supplier of recombinant
'/>"/>

SOURCE Repligen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen Announces Conference Call of Third Quarter Fiscal Year 2008 Results
2. Repligen Announces Settlement with Bristol-Myers Squibb in Orencia(R) Lawsuit
3. Repligen Reports Fourth Quarter and Fiscal Year 2008 Financial Results
4. Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results
5. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
6. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
7. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
8. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
9. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
10. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
11. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... Selexis SA , a serial innovation ... mammalian cell line development, announced today new data from ... presented at the 10th Annual Cell Line Development ... 10, 2014 at the Double Tree by Hilton Berkeley ... will be presented during an oral presentation: , Title: ...
(Date:7/30/2014)... BCC Research ( http://www.bccresearch.com ) reveals in ... Industrial Applications , the global market for industrial enzymes ... 2018, registering a five-year compound annual growth rate (CAGR) ... in the detergent enzyme segment with a CAGR of ... influenced almost every sector of industrial activity, ranging from ...
(Date:7/30/2014)... 30, 2014 Researchers often use microelectronic ... but such devices can do much more – ... such, researchers have looked to patterned assemblies of ... metabolic engineering to characterize – and potentially control ... are envisioned to recreate animal and human physiological ...
(Date:7/30/2014)... Hartford, CT (PRWEB) July 30, 2014 ... economic development organization based in East Hartford, Conn., was ... on Phase II of a project that will determine ... facility in rural north-central Connecticut. USDA Rural Development provided ... (RBEG) program for the second phase of the feasibility ...
Breaking Biology Technology:Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 2Selexis SA to Present New Data and a Case Study at IBC’s Cell Line Development and Engineering Conference 3Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 2Global Market for Industrial Enzymes to Reach Nearly $7.1 Billion by 2018; Detergent Enzyme Market to Record Maximum Growth 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 2UMD Researchers Bridge Gap between Microelectronics, Biological Systems 3UMD Researchers Bridge Gap between Microelectronics, Biological Systems 4USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 2USDA Grant Funds Second Phase of Bio-Energy Research Community Economic Development in CT 3
... WASHINGTON, Oct. 19 The US and European medical ... growth in 2009 but managed to improve overall net ... improved financial discipline. While medtech has fared better than ... will put increasing strain on the industry,s long-standing business ...
... Co. (NYSE: GRA ) has received approval from ... of the previously announced transactions contemplated by the Agreement and ... to which W. R. Grace & Co.-Conn, a wholly-owned subsidiary ... (OTC Bulletin Board: NZYM ), a manufacturer of ...
... Theoretical work done at the Department of Energy,s Oak ... an unexpected magnetism between two dissimilar materials. The ... significance for the design of future electronic devices for ... ORNL,s Materials Science and Technology Division. The work was ...
Cached Biology Technology:Medtech Industry Successfully Weathering Challenges of Economic Downturn 2Medtech Industry Successfully Weathering Challenges of Economic Downturn 3Medtech Industry Successfully Weathering Challenges of Economic Downturn 4Medtech Industry Successfully Weathering Challenges of Economic Downturn 5Synthetech Announces Bankruptcy Court Approval of Merger With W. R. Grace Subsidiary 2Synthetech Announces Bankruptcy Court Approval of Merger With W. R. Grace Subsidiary 3ORNL theorist part of team that discovers unexpected magnetism 2
(Date:7/30/2014)... Everybody knows the shortest distance between two points is ... that sperm have been taking the familiar axiom to ... usually thought to be intense, with each racing for ... in some species, sperm form cooperative groups that allow ... , A new study, conducted by Heidi Fisher, ...
(Date:7/30/2014)... joint venture between The University of Texas at San ... Center at San Antonio, has selected the winners of ... from UTSA and Lei Huang from the Health Science ... engineered ferritins for tracking and protecting neural stem cells ... focused on finding a treatment for stroke through stem ...
(Date:7/30/2014)... Jackson Laboratory has received a pledge of $1 million ... name the Laboratory,s new Neurobehavioral Biometry Center. ... Center will enable the Laboratory to develop a greater ... the ultimate goal of accelerating the pace of research ... serve as a premier resource for the Laboratory and ...
Breaking Biology News(10 mins):When cooperation counts 2When cooperation counts 3Rossi Foundation pledges $1M for JAX neurobehavioral research center 2
... Our cells, molecules form an intricate network of ... to measure individual molecular reactions outside the cells. ... than in the laboratory, scientists suspect that the ... substantially from external probes. We expected the cellular ...
... School of Medicine researcher will lead the coordinating center ... in the field of stem cell research. Michael L. ... chosen by the National Heart, Lung and Blood Institute ... national experts, which will be called the NHLBI Progenitor ...
... , WALL, N.J., Dec. 3 BIO-key International, ... public safety and finger-based biometric identification solutions, announced that ... Meeting held today approved the sale of the company,s ... the shares voted, 98.6% were cast in favor and ...
Cached Biology News:Looking for the heartbeat of cellular networks 2University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 2University of Maryland School of Medicine receives $30 million to coordinate stem cell consortium 3BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 2BIO-key(R) Shareholders Overwhelmingly Approve Sale of Law Enforcement Division 3
Mouse polyclonal antibody raised against a partial recombinant AGTRAP. NCBI Entrez Gene ID = 57085...
Mouse monoclonal antibody raised against a partial recombinant RAB11B. NCBI Entrez Gene ID = RAB11B...
... polyclonal antibody raised against a ... Immunogen: SF3B2 (NP_006833, ... partial recombinant protein with GST ... Number: NM_006842 ...
...
Biology Products: